

APPENDIX U- Declarations of interests

1.1 Introduction

All members of the GDG and all members of the NCGC staff were required to make formal declarations of interest at the outset of each meeting, and these were updated at every subsequent meeting throughout the development process.

Declarations of interests of the GDG members

| | |
|---|----------|
| APPENDIX U- DECLARATIONS OF INTERESTS | 1 |
| 1.1 INTRODUCTION | 1 |
| 1.1.1 <i>Dr Nick Kosky (Chair)</i> | 2 |
| 1.1.2 <i>Professor Helen Cross (Clinical Advisor)</i> | 3 |
| 1.1.3 <i>Mrs Tracey Truscott</i> | 4 |
| 1.1.4 <i>Mrs Diane Flower</i> | 5 |
| 1.1.5 <i>Professor John Duncan</i> | 5 |
| 1.1.6 <i>Dr Margaret Jackson</i> | 7 |
| 1.1.7 <i>Dr Richard Appleton</i> | 8 |
| 1.1.8 <i>Dr Greg Rogers</i> | 11 |
| 1.1.9 <i>Mr Sean Mackey</i> | 12 |
| 1.1.10 <i>Mr Michael Harnor</i> | 13 |
| 1.1.11 <i>Mrs Sally Gomersall</i> | 14 |
| 1.1.12 <i>Dr Amanda Freeman</i> | 15 |
| 1.1.13 <i>Dr Ian Chi Kei Wong</i> | 16 |
| 1.1.14 <i>Michael Marsh (co-opted expert)</i> | 17 |
| 1.1.15 <i>Dr Aza Abdulla (co-opted expert)</i> | 18 |
| 1.1.16 <i>Professor Frank Besag (co-opted expert)</i> | 19 |
| 1.2 DECLARATIONS OF INTERESTS OF THE NCGC MEMBERS | 20 |
| 1.3 DECLARATIONS OF INTERESTS OF EXPERT PEER REVIEWERS..... | 21 |

1.1.1 Dr Nick Kosky (Chair)

| GDG meeting | Declaration of Interests |
|---|--|
| On Application | None directly relevant. Sits on a variety of advisory boards and speaker panels for the pharmaceutical industry, but these relate to antidepressants and antipsychotics and the treatment of psychosis, mood and anxiety disorders. Has no involvement with the development, marketing, surveillance of anticonvulsants or, save where they are used in the treatment of bipolar disorder, teaching or training concerning these drugs. As part of the appointment, all remunerated activities with the pharmaceutical company will cease. Any relationship with a manufacturer of an anticonvulsant will cease. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |
| Ninth GDG Meeting 14th May 2010 | No interests to declare. |
| Ninth GDG Meeting (10th June 2010) | No interests to declare. |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (09th February 2011) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | No interests to declare. |

1.1.2 Professor Helen Cross (Clinical Advisor)

| GDG meeting | Declaration of Interests |
|---|--|
| On Application | Educational grants for travel and honoraria for lectures received from UCB, Eisai SHS International and Janssen Cilag. Contribution to funding of an annual 'Epilepsy Training Fellowship' within the Neuroscience Unit, Great Ormond Street Hospital for Children NHS Trust by Janssen Cilag, UCB and Eisai. Medical advisor to 'Matthews Friends' a parent support group for families of children on the ketogenic diet. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare |
| Third GDG Meeting (17th September 2009) | 13.09.09- Nutricia Symposium at EFND. 16.09.09 Education talk on Ketogenic diet for Nutricia, Honoraria department. |
| Fourth GDG Meeting (6th November 2009) | Conducted educational lectures for Neutricia (Sept 09, Florence and a webinar) and UCB (Leuven) October 2009. Honorarium paid to the department (Neurosciences Unit UCL-ICH). A co-author of one of the Ketogenic Diet studies. |
| Fifth GDG Meeting (11th December 2009) | No interests to declare |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare |
| Seventh GDG Meeting (11th March 2010) | No interests to declare |
| Eight GDG Meeting (29th April 2010) | No interests to declare |
| Ninth GDG Meeting 14th May 2010 | No interests to declare |
| Tenth GDG Meeting (10th June 2010) | Talk at Educational Symposia Sponsored by VCB Honorarium Department. Reporting as expert in review of Sodium Valproate use in pregnancy. Expert in Neurological Outcome review in 10 test cases. Expert witness for sanofi in the litigation case on effect of sodium valproate on unborn child, all funds going to the department Spoke at an SHS symposia in Egypt at ICNA on ketogenic diet but did not receive payment. A co-author of one of the Ketogenic Diet studies. |
| Tenth GDG Meeting (21st October 2010) | A co-author of one of the Ketogenic Diet studies. |
| Eleventh GDG Meeting (09th February 2011) | A co-author of one of the Ketogenic Diet studies. |
| Twelfth GDG Meeting (21st June 2011) | EISAI: spoke at educational symposium cavtat croatia (epns) and at the educational symposium St Petersburg. Consultant for GSK study: consultant UCL |
| Thirteenth GDG Meeting (7th September 2011) | Donation by Eisai and UCB to department for ongoing funding of epilepsy fellowship. Sat on an advisory board for Viropharma (Buccal Midazolam). Contract and reimbursements with employer (UCL) and to department. |

| GDG meeting | Declaration of Interests |
|---|---|
| From September to December 2011 outstanding DOIs | Communicated with Viropharma for which consultant fees went to department Spoke at masterclass sponsored by Special Products |
| Actions | At the November 2009, 10 th June and 21 st October 2010 GDG meetings, Helen acted as an expert on Ketogenic Diet and not as a GDG member when discussing recommendations related to the ketogenic diet. |

1.1.3 Mrs Tracey Truscott

| GDG meeting | Declaration of Interests |
|---|--|
| On Application | UCB drug representative provides light refreshments for monthly Kent and Kings Specialist nurse meetings for which I attend. An epilepsy master class was held in April 2009. UCB sponsored all attendees. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |
| Ninth GDG Meeting 14th May 2010 | Attendance at Best Value, Better Care Commissions Epilepsy services 23/12/10. A one to one meeting with the UCB rep to discuss Buccal Midazolam |
| Tenth GDG Meeting (10th June 2010) | Attendance at epilepsy master class sponsored by UCB |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (09th February 2011) | Did not attend |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | Promoting letter of support for the prescribing of epistatins for special products ltd. |

1.1.4 Mrs Diane Flower

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | No interests to declare. |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | In addition to her role as lead children's epilepsy specialist nurse in Newport, she is now also working part-time as tuberous sclerosis specialist nurse at the RUH in Bath. |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |
| Eight GDG Meeting (29th April 2010) | Has organised a study day (13th May) for 20 people and lunch will be paid for by Special Products (Does not know the exact cost). She also attended a meeting on the 22nd March that was sponsored by Eisai and UCB pharma. |
| Ninth GDG Meeting 14th May 2010 | Did not attend |
| Ninth GDG Meeting (10th June 2010) | Colleague on my team has applied for funding (approx £300) from UCB pharma to attend a conference |
| Tenth GDG Meeting (21st October 2010) | UCB pharma paid £350 towards attendance at the ILAE conference last week |
| Eleventh GDG Meeting (09th February 2011) | Did not attend |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | No Interests to declare |

1.1.5 Professor John Duncan

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| On Application | Previous lecture fees from UCB Pharma, Janssen-Cilag. Advisory Boards for Sanofi Aventis, Eisai, GlaxoSmithKline, GE Healthcare. Grants to support research and education events from UCB Pharma, GlaxoSmithKline, Eisai, Janssen- Cilag. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | EISAI/UCB/Janssen – fees to UCL for arranging meetings and giving lectures. |
| Fourth GDG Meeting (6th November 2009) | Did not attend |

| GDG meeting | Declaration of Interests |
|---|--|
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |
| Eight GDG Meeting (29th April 2010) | Attended the ABPI Annual dinner on the 27th April at the invitation of UCB. |
| Ninth GDG Meeting 14th May 2010 | Did not attend |
| Ninth GDG Meeting (10th June 2010) | Participation in ad hoc meetings of MHRA branded prescribing working group on 13 th May 2011. Fee paid to UCL to chair and speak at Satellite Symposium at European Epilepsy Congress, 27 June 2010. Travel , accommodation and Conference registration paid by Glaxo Smith Kline (GSK). |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (09th February 2011) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | Consultancy fee from Cyberonics and fee from Eisai for organising symposium November payable to UCL. Participation in round table on neurological commissioning with GSK, UCB, Eisai, Janssen Cillag with links to VNS. Organisation sponsored by these companies. |
| Any further DOIs between September and December 2011 | Participation in ad hoc meetings of MHRA branded prescribing working group on 14 October 2011. 3 to 7 Dec ember 2011 attended an American Epilepsy Society with costs covered by GSK. 6 December attended an advisory board on perampanel for Eisai |

1.1.6 Dr Margaret Jackson

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|--|
| On Application | No non-personal pecuniary interests within the last 12 months- the neurology department received £15000 from UCB 15 months ago to support the construction of a database for patients with epilepsy. No personal non-pecuniary interests within the last year. I have done review articles in the past on management of epilepsy expressing views on drug management for peer-reviewed journals. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | UCB will be sponsoring a regional epilepsy meeting on September 18 th for Newcastle/Middlesborough. |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | Giving a presentation on the 12 th November 2009 on neurodevelopment and epilepsy to SpRs funded by Esai, with the honorarium going to the research fund. Also attending a UCB sponsored meeting in Hampshire later in November. |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |
| Ninth GDG Meeting 14th May 2010 | No interests to declare. |
| Ninth GDG Meeting (10th June 2010) | No interests to declare. |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (09th February 2011) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | No interests to declare. |
| Thirteenth GDG Meeting (7th September 2011) | Did not attend |

1.1.7 Dr Richard Appleton

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| On Application | I have, within the past five years received honoraria and consultancy fees from the following pharmaceutical companies: Eisai, GlaxoSmithKline, Janssen-Cilag, Parke-Davis, Sanofi-Aventis, Special Products Ltd, UCB Pharma. I have no current active or ongoing pecuniary interests or pecuniary commitments/contracts with the pharmaceutical industry. |
| First GDG meeting (12th May 2009) | I have within the past four weeks (April 6 th 2009) had confirmation that a pharmaceutical company, Eisai, will sponsor a booklet on 'Epilepsy for siblings' that I am co-editing with a Clinical Psychologist. The sponsorship is for the publication costs of the book and I will receive no financial 'reward' or like reward for publishing the book. There will be no royalties arising from the book which will be distributed free of charge. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | Did not attend |
| Fourth GDG Meeting (6th November 2009) | Recent advice and consultations (as yet unpaid) provided to a new pharmaceutical company (Mitovie) regarding the introduction of a new formulation of emergency medication to treat tonic clonic seizures including convulsive status epilepticus. These consultations will continue and in 2010 are likely to be more formally based with advisory or consultancy fees. |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | Has been invited to speak, with honoraria, at the following academic meetings in May: <ul style="list-style-type: none"> • Epilepsy Masterclass; a series of tutorials on the transitional care of young people with epilepsy and learning difficulties sponsored by UCB Pharma. No action required. • A one-day course on Paediatric Epilepsy sponsored by Healthcare Education Services for the pharmaceutical industry (this two-day course is arranged by Healthcare Services and is attended by representatives of those pharmaceutical companies who manufacture, or who are in the process of developing novel antiepileptic drugs). No action required. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |

| GDG meeting | Declaration of Interests |
|---|--|
| Ninth GDG Meeting (10th June 2010) | <p>Secretary of the local (Merseyside, North Wales and Cheshire) paediatric epilepsy network, called 'EPIC' (Epilepsy In Children). This network has been running for 10 years and one pharmaceutical company meets the costs of the meetings (hire costs of the venue, A-V equipment and evening buffet) for two consecutive years, after which sponsorship is taken on by another company. UCB Pharma is sponsoring EPIC for 2009 and 2010</p> <p>Has been asked to provide some consultancy work for GSK from July 2010. This will relate to work on a novel antiepileptic drug, and not on one of GSK's current and licensed antiepileptic drugs.</p> <p>Will be running a series of seminars (an 'Epilepsy Masterclass') on the transition of young people with epilepsy with learning difficulties from paediatric to adult care in September 2010. Will receive a single honorarium for this 'Epilepsy Masterclass' from UCB Pharma.</p> <p>Principal Investigator for two RCTs included in the scope of this guideline- vigabatrin in infantile spasms and gabapentin in partial seizures.</p> |
| Tenth GDG Meeting (21st October 2010) | <p>Honoraria for two Advisory Board Meetings as an expert in Paediatric Epilepsy for UCB (September and November 2010) on its new anticonvulsant, lacosamide (Vimpat)</p> <p>Honorarium for a series of tutorials given in a UCB-funded Epilepsy Masterclass Series on 'Transitional issues in young people with epilepsy and learning disabilities' (September 2010)</p> <p>Expenses-paid lecture by UCB to give an invited lecture on 'Steroids and Epilepsy' to the Norwegian Branch of the International League Against Epilepsy at their annual meeting in Oslo, Norway (November 2010). No honorarium will be received for the lecture.</p> <p>Chief Investigator for a UCB Pharma-funded national observational study on the use of oral levetiracetam (Keppra) in infants under 12 months of age. I will receive no fee for this study but for each child recruited into the study, the Epilepsy Research Fund at Alder Hey Children's Hospital (AHCH) will receive a fixed payment. This study and per-patient payment has been approved by the Research and Development Committee at AHCH.</p> |
| Eleventh GDG Meeting (09th February 2011) | Did not attend. |
| Twelfth GDG Meeting (21st June 2011) | <p>UCB Pharma-awarded sponsorship (approximately £4000 over 2 years) to design and pilot an International Paediatric Epilepsy training course – in response to my approach to UCB Pharma on behalf of the British Paediatric Neurology Association)</p> <p>Sponsorship by Eisai to attend the International Epilepsy congress in Rome in Aug/Sep 2011</p> |
| Thirteenth GDG Meeting (7th September 2011) | Eisai sponsors our regional epilepsy network meetings (EPIC) which includes hire of a room in a hotel, AV equipment and buffet dinner for 20-30 people (x 3 a year). This will be for 2011 and 2012. |

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---------------------------|---|
| Actions | As principal Investigator for two RCTs included in the scope of this guideline- vigabatrin in infantile spasms and gabapentin in focal seizures, Dr Appleton acted as an expert and not as a GDG member at the June and October 2010 GDG meetings when discussing recommendations related to infantile spasms and focal seizures. |

1.1.8 Dr Greg Rogers

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|--|--|
| On Application | Resigned from being a UCB advisor on July 22 nd 2008 when joining the TLOC GDG and have not received any payment. Editor of Synapse Primary Care neurological magazine sponsored by UCB/Orion/GSK. Received £700 last year for this- the publication is supported by an unconditional grant from UCB. Have contacted the company Oyster who publish the magazine and asked for payment to cease until 2010 when the GDG work is complete. Sponsorship to attend ILAE Conference in Berlin Autumn 08 by UCB. East Kent Epilepsy team meeting sponsored by UCB however the last time payment was accepted was 20 th March 2008 for £1000. So far it has only been UCB who have been involved however if acceptable I will approach other pharmaceutical companies to vary the sponsorship. One alternative is to approach the PCT. Invite to Hungarian ILAe meeting in June by Eisai, which has been declined and I do not plan to take up any offers while working on this GDG. Previously medical advisor for UCB. Honorarium from Royal Society of Medicine Autumn 08 talk on Blackouts. Plan to attend the ILAE GPwSI meeting in May. It is going to be hosted by the ILAE however it is sponsored by Eisai. Previously director of Primary Care Neurological Society. Clinical Advisor for Epilepsy Action and Epilepsy Bereaved. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | Appointment to Panel B of the Guideline Review Panel |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | No interests to declare |
| Fifth GDG Meeting (11th December 2009) | No interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare. |
| Seventh GDG Meeting (11th March 2010) | Did not attend |
| Eight GDG Meeting (29th April 2010) | Did not attend |
| Ninth GDG Meeting 14th May 2010 | On May 13th gave an update on Epilepsy at the Imperial College GP update meeting with an honorarium of £150. No action required. |
| Ninth GDG Meeting (10th June 2010) | No interests to declare. |
| Tenth GDG Meeting (21st October 2010) | Has started as a professional member of the Acute and Chronic Conditions Topic Selection consideration panel with a term of office will be for three years in the first instance, commencing on the 1 November 2010 and ending in November 2013. |
| Eleventh GDG Meeting (9th February 2011) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | Participation in round table on neurological commissioning with link to support vagal nerve stimulation. Put forward by Cyberonics. |

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| Thirteenth GDG Meeting (7th September 2011) | <p>To join VNS Clinical Advisory Group that will help lobby the retention of VNS.</p> <p>June 9th - 10th I attended the ILAE GP Society meeting which was organised by the ILAE sponsored by Eisai i.e. indirect.</p> <p>I resigned as being one of the directors for the Primary Care Neurological Society years before the start of the GDG, I had not realised I was mentioned on their web site as being currently on their steering committee. There has been no financial link at all and I have asked them to take kindly take my name off the web site.</p> |

1.1.9 Mr Sean Mackey

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|--|
| On Application | I have received funding from Consultancy companies providing advisory panels on behalf of the Pharmaceutical Industry, but none for antiepileptic medication. |
| First GDG meeting (12th May 2009) | <p>Facilitated and spoke at national events around the National Patient Safety Association Rapid Response Alerts around Strong Opioids, hosted by Pharmacy Management and sponsored by Napp pharmaceuticals. Paid directly by Pharmacy Management Limited.</p> <p>Participated in an Advisory Panel around the use of Ezetimibe hosted by HGS Consultancy and sponsored by Schering Plough.</p> <p>Expect to be involved in consultancy work that may be indirectly/directly funded by the Pharmaceutical Industry over the next 12 months but not associated with AEDs or Epilepsy.</p> |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | No interests to declare |
| Fifth GDG Meeting (11th December 2009) | Did not attend |
| Sixth GDG Meeting (2nd February 2010) | Did not attend |
| Seventh GDG Meeting (11th March 2010) | Resigned from GDG due to personal reasons |

1.1.10 Mr Michael Harnor

| GDG meeting | Declaration of Interests |
|--|--|
| On Application | I have stocks and share ISA administrated on a nominee basis by Barclays. This contains 37 ord shares in Astra Zeneca, 56 ord shares in GlaxoSmithKline and 197 ord shares in Smith and Nephew. Also 440 ord shares in Finsbury Worldwide Pharmaceutical Trust. I am national Chairman and senior trustee of The British Epilepsy Association (working name 'Epilepsy Action'): a registered charity and company limited by guarantee. We obtain from time to time donated funds from pharmaceutical companies but the Association operates a strict sponsorship policy which limits the proportion of our funds obtained from such sources and also strictly confines the purpose to which such funds can be put. Such funds are always used solely to further our particular charitable objective. We would also expect any supporters to be adhering to the industry codes of practice. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | Did not attend |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | No interests to declare |
| Fifth GDG Meeting (11th December 2009) | No interests to declare |
| Sixth GDG Meeting (2nd February 2010) | The Commission on Human Medicines has reduced its Expert Advisory Groups into a smaller number. The neurology EAG no longer exists. However, he is now Lay Member of the neurology, pain and psychiatry Expert Advisory Group. This means that he remains a lay member at the MHRA which hosts the CHM. |
| Seventh GDG Meeting (11th March 2010) | 1) Has been appointed to the Commission on Human Medicines Expert Advisory Group on Neurology, Pain and Psychiatry. This will extend to 2013. 2) On 23rd February 2010, he attended with no venue costs a London conference 'Better Value, Better Care - Commissioning Epilepsy Services' which was substantially funded by UCB Pharma. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |
| Ninth GDG Meeting 14th May 2010 | No interests to declare. |
| Ninth GDG Meeting (10th June 2010) | 6 th July Manchester. Will attend and contribute to the north west regional follow up of 'Better Value, Better Care – Commissioning Epilepsy Services'. Venue and subsistence costs paid by UCB Pharma. |
| Tenth GDG Meeting (21st October 2010) | Appointed to the Patient Information Advisory Group by the Commission on Human Medicines (PIAG). The second group of which he is a member of which advises CHM. |
| Eleventh GDG Meeting (9th February 2011) | No interests to declare. |

| GDG meeting | Declaration of Interests |
|---|---------------------------------|
| Twelfth GDG Meeting (21st June 2011) | No interest declared |
| Thirteenth GDG Meeting (7th September 2011) | No interest declared |

1.1.11 Mrs Sally Gomersall

| GDG meeting | Declaration of Interests |
|---|---|
| On Application | No interests to declare. Interest declared on the 1 st March 2009- Recently been filmed for an educational DVD; Taking the Tablets, funded by an education grant from Janssen Cilag. |
| First GDG meeting (12th May 2009) | No interests to declare. |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare |
| Fourth GDG Meeting (6th November 2009) | No interests to declare |
| Fifth GDG Meeting (11th December 2009) | No interests to declare |
| Sixth GDG Meeting (2nd February 2010) | Will speak at the Best Value, Better Care – Commissioning Epilepsy Services conference on Tuesday 23 February 2010 Holiday Inn London - Kensington Forum. The conference is funded by UCB |
| Seventh GDG Meeting (11th March 2010) | No interests to declare |
| Eight GDG Meeting (29th April 2010) | No interests to declare |
| Ninth GDG Meeting 14th May 2010 | No interests to declare |
| Ninth GDG Meeting (10th June 2010) | On 2.7.09 I was elected to the Executive Committee at the Joint Epilepsy Council |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (9th February) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | Epilepsy society Joint Epilepsy council Epilepsy Action National Centre for young people with epilepsy |
| Thirteenth GDG Meeting (7th September 2011) | No interests to declare. |

1.1.12 Dr Amanda Freeman

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | Declaration of membership to the Epilepsy action Professionals Advisory Panel |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare. |
| Fourth GDG Meeting (6th November 2009) | No interests to declare. |
| Fifth GDG Meeting (11th December 2009) | I have recently organised a Regional Paediatric Epilepsy Interest Group Meeting with total sponsorship amounting to £1500 approx to ensure that the meeting is free for non-medical staff, from the following companies: UCB, Cyberonics, Janssen-Cilag. |
| Sixth GDG Meeting (2nd February 2010) | No interests to declare |
| Seventh GDG Meeting (11th March 2010) | No interests to declare |
| Eight GDG Meeting (29th April 2010) | Did not attend. However, still declared that received £250 from Eisai in her capacity as Chair of the Wessex Paediatric Neurosciences Group to pay for room hire for their Multidisciplinary Regional Paediatric Epilepsy Study Day. The Rep also recently provided a sandwich lunch for our Departmental Grand Round. No action required. |
| Ninth GDG Meeting 14th May 2010 | Departmental 'Ground Round' Sponsorship (lunch only), UCB Pharma and SHS International. Regional Epilepsy Interest Group Meeting (£1000 UCB). Member of Epilepsy Action Professionals Advisory Panel (ongoing) |
| Ninth GDG Meeting (10th June 2010) | No interests to declare. |
| Tenth GDG Meeting (21st October 2010) | No interests to declare. |
| Eleventh GDG Meeting (9th February 2011) | No interests to declare. |
| Twelfth GDG Meeting (21st June 2011) | No interests to declare. |
| Thirteenth GDG Meeting (7th September 2011) | Sandwich lunch supporting educational meetings from UCB, Beacon, Epilepsy Action. |

1.1.13 Dr Ian Chi Kei Wong

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|--|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | Did not attend |
| Second GDG Meeting (14th July 2009) | Did not attend |
| Third GDG Meeting (17th September 2009) | Did not attend |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | Did not attend |
| Sixth GDG Meeting (2nd February 2010) | Did not attend |
| Seventh GDG Meeting (11th March 2010) | Director and Founder: A School of Pharmacy, University of London Spin-out company 'Therakind' which is currently developing buccal midazolam for seizure treatments. Expert witness: Arnold and Porter LLP, a legal case related to epilepsy treatment. He has published several papers which reported that the treatments and research of epilepsy need to be improved. |
| Eight GDG Meeting (29th April 2010) | No interests to declare. |
| Ninth GDG Meeting 14th May 2010 | No interests to declare. |
| Ninth GDG Meeting (10th June 2010) | Director and Founder: A School of Pharmacy, University of London Spin-out company 'Therakind' which is currently developing buccal midazolam for seizure treatments. |
| Tenth GDG Meeting (21st October 2010) | Director and Founder: A School of Pharmacy, University of London Spin-out company 'Therakind' which is currently developing buccal midazolam for seizure treatments. |
| Eleventh GDG Meeting (9th February 2011) | Did not attend |
| Twelfth GDG Meeting (21st June 2011) | Did not attend |
| Thirteenth GDG Meeting (7th September 2011) | Did not attend |
| Actions | At the June and October 2010 GDG meetings, Professor Wong acted as an expert and not as a GDG member when discussing recommendations related to buccal midazolam. |

1.1.14 Michael Marsh (co-opted expert)

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---------------------------------|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | Did not attend |
| Second GDG Meeting (14th July 2009) | Did not attend |
| Third GDG Meeting (17th September 2009) | Did not attend |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | Did not attend |
| Sixth GDG Meeting (2nd February 2010) | Did not attend |
| Seventh GDG Meeting (11th March 2010) | No interests to declare. |

1.1.15 Dr Aza Abdulla (co-opted expert)

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|--|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | Did not attend |
| Second GDG Meeting (14th July 2009) | Did not attend |
| Third GDG Meeting (17th September 2009) | Did not attend |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | Did not attend |
| Sixth GDG Meeting (2nd February 2010) | Did not attend |
| Seventh GDG Meeting (11th March 2010) | Member of the Clinical Effectiveness and Practice Committee of the British Geriatric Society |

1.1.16 Professor Frank Besag (co-opted expert)

| <i>GDG meeting</i> | <i>Declaration of Interests</i> |
|---|---|
| On Application | No interests to declare. |
| First GDG meeting (12th May 2009) | Did not attend |
| Second GDG Meeting (14th July 2009) | Did not attend |
| Third GDG Meeting (17th September 2009) | Did not attend |
| Fourth GDG Meeting (6th November 2009) | Did not attend |
| Fifth GDG Meeting (11th December 2009) | Did not attend |
| Sixth GDG Meeting (2nd February 2010) | Did not attend |
| Seventh GDG Meeting (11th March 2010) | Frank Besag has received lecture fees, consultancy fees, research grants and equipment grants from and has been sponsored to conferences by various pharmaceutical companies. He was previously editor-in-chief of a journal sponsored by GSK. He is currently receiving no monies from pharmaceutical companies, nor from any source other than his employer, the NHS in the UK. |

1.2 Declarations of interests of the NCGC members

| GDG meeting | Declaration of Interests of the NCGC members |
|---|--|
| On Application | No interests to declare |
| First GDG meeting (12th May 2009) | No interests to declare |
| Second GDG Meeting (14th July 2009) | No interests to declare. |
| Third GDG Meeting (17th September 2009) | No interests to declare |
| Fourth GDG Meeting (6th November 2009) | Vanessa Nunes: Her partner is currently the director of a consultancy company for health economics and outcomes research and the company works with several pharmaceutical companies. There is however a clause in the contracts , which stipulates that the companies and pharmaceuticals they are working on are confidential. |
| Fifth GDG Meeting (11th December 2009) | No new interests to declare. |
| Sixth GDG Meeting (2nd February 2010) | No new interests to declare. |
| Seventh GDG Meeting (11th March 2010) | No new interests to declare. |
| Eight GDG Meeting (29th April 2010) | No new interests to declare. |
| Ninth GDG Meeting (10th June 2010) | No new interests to declare. |
| Tenth GDG Meeting (21st October 2010) | No new interests to declare. |
| Eleventh GDG Meeting (9th February 2011) | No new interests to declare. |
| Twelfth GDG meeting (21st June 2011) | No new interests to declare. |
| Thirteenth GDG Meeting (7th September 2011) | No new interests to declare. |

1.3 Declarations of interests of expert peer reviewers

| <i>Expert peer reviewer</i> | <i>Declaration of Interests of the expert peer reviewers</i> |
|-----------------------------|---|
| Catrin Tudur Smith | <p>Statistical editor of the Cochrane Epilepsy Group, which has produced numerous reviews, including IPD review, that are relevant to the epilepsy guideline.</p> <p>Trial statistician of the SANAD trial, the results of which in part triggered the NICE guidelines update.</p> |
| Anthony Marson | <p>Advisory Board for UCB regarding trial design for lacosamide and breviracetam studies, November and December 2011.</p> <p>The National Audit of Seizures in Hospitals (NASH) is funded from a consortium of companies (GSK, UCB, Eisai) who have paid grants to the University of Liverpool.</p> <p>Coordinating Editor of the Cochrane Epilepsy Group, which has produced numerous reviews, including IPD reviews, that are relevant to the epilepsy guidelines.</p> <p>Joint chief investigator of the SANAD trial, the results of which in part triggered the NICE guidelines update.</p> <p>Director of the UK Epilepsy Research Network</p> |